Table 5.

Multivariate Cox proportional-hazards regression analyses of cardiac biomarkers on risk of in-hospital death in all study population, cardiac, and non-cardiac patients.

	Biomarkers	Unadjusted		Model 1		Model 2		Model 3
		HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
All included patients (n = 1,023)	Hs-TnI, per 10 pg/mL	1.002 (1.001–1.003)	<0.001	1.002 (1.001–1.002)	<0.001	1.002 (1.001–1.002)	<0.001	1.001 (1.000–1.002)	0.184
	CK-MB, per 1 ng/mL	1.078 (1.053–1.103)	<0.001	1.047 (1.021–1.073)	<0.001	1.052 (1.022–1.083)	0.001	0.996 (0.964–1.030)	0.825
	Myo, per 10 ng/mL	1.029 (1.023–1.035)	<0.001	1.024 (1.017–1.030)	<0.001	1.026 (1.019–1.032)	<0.001	1.010 (1.002–1.017)	0.012
	NT-proBNP, per 100 pg/mL	1.015 (1.010–1.019)	<0.001	1.012 (1.008–1.017)	<0.001	1.013 (1.008–1.018)	<0.001	1.006 (1.000–1.013)	0.049
Non-cardiac patients (n = 897)	Hs-TnI, per 10 pg/mL	1.002 (1.001–1.003)	<0.001	1.002 (1.001–1.002)	<0.001	1.002 (1.001–1.002)	<0.001	1.001 (1.000–1.001)	0.172
	CK-MB, per 1 ng/mL	1.117 (1.088–1.146)	<0.001	1.097 (1.067–1.129)	<0.001	1.093 (1.062–1.126)	<0.001	1.000 (0.959–1.043)	0.990
	Myo, per 10 ng/mL	1.031 (1.024–1.037)	<0.001	1.026 (1.019–1.032)	<0.001	1.029 (1.021–1.036)	<0.001	1.009 (1.000–1.018)	0.038
	NT-proBNP, per 100 pg/mL	1.018 (1.012–1.023)	<0.001	1.018 (1.013–1.024)	<0.001	1.018 (1.011–1.024)	<0.001	1.010 (1.001–1.020)	0.034
Cardiac patients (n = 126)	Hs-TnI, per 10 pg/mL	0.999 (0.990–1.008)	0.781	0.998 (0.986–1.010)	0.709	0.998 (0.986–1.010)	0.722	0.992 (0.977–1.007)	0.308
	CK-MB, per 1 ng/mL	0.996 (0.900–1.101)	0.934	0.989 (0.897–1.090)	0.822	0.989 (0.892–1.097)	0.830	0.947 (0.854–1.050)	0.300
	Myo, per 10 ng/mL	1.019 (1.001–1.036)	0.037	1.014 (0.995–1.032)	0.146	1.018 (0.996–1.041)	0.116	1.003 (0.978–1.028)	0.834
	NT-proBNP, per 100 pg/mL	1.009 (1.001–1.018)	0.025	1.008 (1.000–1.016)	0.056	1.007 (0.999–1.016)	0.101	1.002 (0.991–1.013)	0.719

Model 1: Adjusted for age and sex. Model 2: Model 1 plus comorbidities (cardiac disease, hypertension, diabetes, chronic liver disease, stroke, chronic kidney disease, chronic obstructive pulmonary disease, and cancer). Model 3: Model 2 plus inflammatory and coagulation factors (platelet, D-dimer, neutrophil, high sensitivity C-reactive protein, and interleukin 2 receptor). HR, hazards ratio; CI, confidence interval; Hs-TnI, High sensitivity troponin-I; CK-MB, creatine kinase-MB; Myo, myoglobin; NT-proBNP, N terminal pro B type natriuretic peptide. The bold p values mean that they are of significance in statistics.